Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future

doi:10.1007/s11307-021-01688-9

	Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future
	Cheng, Zhongquan 1,2; Du, Yang2,3 ; Yu, Leyi 1; Yuan, Zhu 1; Tian, Jie 2,3,4,5
发表期刊	MOLECULAR IMAGING AND BIOLOGY
ISSN	1536-1632
	2022-01-31
页码	16
通讯作者	Du, Yang(yang.du@ia.ac.cn) ; Tian, Jie(tian@ieee.org)
摘要	With the application of mono-immunotherapy in cancer, particularly immune checkpoint inhibitors, improved outcomes have been achieved. However, there are several limitations to immunotherapy, such as a poor response to the drugs, immune resistance, and immune-related adverse events. In recent years, studies of preclinical animal models and clinical trials have demonstrated that immune checkpoint inhibitors for breast cancer can significantly prolong the overall survival and quality of patients' lives. Meanwhile, combined immune checkpoint inhibitor treatment has attracted researchers' attention and showed great potential in the comprehensive treatment of breast cancer patients. Additionally, noninvasive imaging enables physicians to predict response to combined immunotherapeutic drugs, achieve treatment efficacy, and lead to better clinical management. Herein, we review the background of combined immune checkpoint inhibitor therapy and summarize its targeted imaging as well as progress in noninvasive imaging aimed at evaluating therapeutic outcomes. Finally, we describe several factors that may influence the outcome of this combined immunotherapy, the future direction of medical imaging, and the potential application of artificial intelligence in breast cancer. With further development of noninvasive imaging for the guidance of combined immune checkpoint inhibitors, cures for this disease may be achieved.
关键词	Noninvasive imaging Immune checkpoint inhibitor Combined immunotherapy Breast cancer
DOI	10.1007/s11307-021-01688-9
关键词[WOS]	NEOADJUVANT CHEMOTHERAPY ; ADJUVANT IMMUNOTHERAPY ; COMBINATION ; BLOCKADE ; THERAPY ; CHALLENGES ; BIOMARKERS ; EFFICACY ; CTLA-4 ; TRASTUZUMAB
收录类别	SCI
语种	英语
资助项目	Beijing Natural Science Foundation[7212207] ; National Natural Science Foundation of China[62027901] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[91859119] ; National Natural Science Foundation of China[61671449] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61901472] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2018PT32003] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2017PT32004] ; National Key R&D Program of China[2018YFC0910602] ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFA0700401] ; National Key R&D Program of China[2016YFA0100902] ; National Key R&D Program of China[2016YFC0103702] ; natural science foundation of beijing municipality[62027901] ; natural science foundation of beijing municipality[81871514] ; natural science foundation of beijing municipality[81227901] ; natural science foundation of beijing municipality[81470083] ; natural science foundation of beijing municipality[91859119] ; natural science foundation of beijing municipality[61671449] ; natural science foundation of beijing municipality[81527805] ; natural science foundation of beijing municipality[61901472]
项目资助者	Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences ; National Key R&D Program of China ; natural science foundation of beijing municipality
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000750274000001
出版者	SPRINGER
七大方向——子方向分类	医学影像处理与分析
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/47368
专题	中国科学院分子影像重点实验室
通讯作者	Du, Yang; Tian, Jie
作者单位	1.Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China 2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Key Lab Mol Imaging,State Key Lab Management & Co, Beijing 100190, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100080, Peoples R China 4.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med Sci & Engn, Beijing 100191, Peoples R China 5.Xidian Univ, Sch Life Sci & Technol, Xian 710071, Shaanxi, Peoples R China
第一作者单位	中国科学院自动化研究所
通讯作者单位	中国科学院自动化研究所
推荐引用方式 GB/T 7714	Cheng, Zhongquan,Du, Yang,Yu, Leyi,et al. Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future[J]. MOLECULAR IMAGING AND BIOLOGY,2022:16.
APA	Cheng, Zhongquan,Du, Yang,Yu, Leyi,Yuan, Zhu,&Tian, Jie.(2022).Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.MOLECULAR IMAGING AND BIOLOGY,16.
MLA	Cheng, Zhongquan,et al."Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future".MOLECULAR IMAGING AND BIOLOGY (2022):16.